Stock A226330 SYNTEKABIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News SyntekaBio, Inc.

Equities

A226330

KR7226330009

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
6,780 KRW -4.64% Intraday chart for SyntekaBio, Inc. -7.38% -52.39%
20/06 Syntekabio Signs Memorandum of Understanding with the bioSeedin CI
20/06 SyntekaBio, Inc. signed Memorandum of Understanding to acquire bioSeedin from Acrobiosystems Co.,Ltd.. CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Syntekabio Signs Memorandum of Understanding with the bioSeedin
CI
SyntekaBio, Inc. signed Memorandum of Understanding to acquire bioSeedin from Acrobiosystems Co.,Ltd..
CI
Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024
CI
Syntekabio Announces to Showcase Biologics Discovery Platform At PEGS Boston
CI
SyntekaBio, Inc. announced that it has received KRW 10 billion in funding from Korea Investment Partners Co. Ltd.
CI
Syntekabio to Showcase Innovative AI Drug Discovery Technologies at Bio-IT World
CI
SyntekaBio, Inc. announced that it expects to receive KRW 10 billion in funding from Korea Investment Partners Co. Ltd.
CI
Polarisqb and Syntekabio Sign MOU for Collaborative AI and Quantum-Pored Drug Development Service
CI
SyntekaBio, Inc. announced that it has received KRW 10 billion in funding
CI
SyntekaBio, Inc. announced that it expects to receive KRW 10 billion in funding
CI
Syntekabio Announces the Launch of its Cost-Effective AI-Based Total Solution Service for Finding New Drug Candidates
CI
SyntekaBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Syntekabio, Inc. Launches STB Cloud Worldwide
CI
Advanced AI Drug Development Platform 'DeepMatcher' 2.0 Launches Worldwide (226330.KQ)
AQ
Advanced AI Drug Development Platform 'DeepMatcher®' 2.0 Launches Worldwide (226330.KQ)
EQ
SyntekaBio, Inc. announced that it has received KRW 25 billion in funding from Shinhan Financial Investment Co., Ltd., Saneun Capital Co., Ltd., Best Investment & Securities Co., Ltd., IBK Capital Corporation,KDB Capital Corp., Shinhan Investment Corp., Investment Arm and other investors
CI
SyntekaBio, Inc. announced that it expects to receive KRW 25 billion in funding from Shinhan Financial Investment Co., Ltd., Saneun Capital Co., Ltd., Best Investment & Securities Co., Ltd., IBK Capital Corporation, KDB Capital Corp., Shinhan Investment Corp., Investment Arm and other investors
CI
SyntekaBio, Inc.(KOSDAQ:A226330) added to S&P Global BMI Index
CI
Syntekabio Presents Nonclinical Data of Immuno-Oncologic Agent Stb-C017 At the 2020 AACR Meeting
CI
SyntekaBio, Inc. has completed an IPO in the amount of KRW 19.2 billion.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A226330 Stock
  4. News SyntekaBio, Inc.